Angina (Angina Pectoris) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Angina (Angina Pectoris) – Drugs In Development, 2024 report and make more profitable business decisions.
Angina pectoris is a term that describes chest pain caused by myocardial ischemia. It usually occurs with exertion and is relieved by rest. Angina generally is a symptom of coronary artery disease. In most severe cases, it occurs with minimal effort or at rest. Symptoms include anxiety, increased or irregular heart rate, paleness and cold sweat, and a feeling of doom. Risk factors include smoking, sedentary lifestyle, high blood lipid levels, and hypercholesterolemia.
The Angina (Angina Pectoris) drugs in development market research report provide comprehensive information on the therapeutics under development for Angina (Angina Pectoris), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Angina (Angina Pectoris) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Angina (Angina Pectoris) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 14 molecules, with 14 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Angina (Angina Pectoris) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Angina (Angina Pectoris) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Angina (Angina Pectoris) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Arbor Pharmaceuticals LLCAstraZeneca Plc
Chong Kun Dang Pharmaceutical Corp.
Coeurative Inc
Eight Plus One Pharmaceutical Co Ltd
Gene Biotherapeutics Inc
Hemostemix Inc
Imbria Pharmaceuticals Inc
Innovative Pharmacology Research LLC
Jiangsu Hengrui Medicine Co Ltd
Kuhnil Pharmaceutical Co Ltd
Signal Pharma Ltd
Trizell Ltd
XyloCor Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Angina (Angina Pectoris) reports